Drug class
Intermittent Claudication Agents
Intermittent claudication agents comprise a therapeutic class of vasoactive and hemorheologic medications used to manage ischemic muscle pain and functional walking impairment resulting from peripheral artery disease. Read more about Intermittent Claudication Agents
14 drugs in this class 12 manufacturers
Drugs in Intermittent Claudication Agents
PENTOXIFYLLINE
PENTOXIFYLLINE
CILOSTAZOL
CILOSTAZOL
Intermittent claudication agents comprise a therapeutic class of vasoactive and hemorheologic medications used to manage ischemic muscle pain and functional walking impairment resulting from peripheral artery disease.
The class primarily includes medications such as cilostazol, a phosphodiesterase-3 inhibitor that induces vasodilation and inhibits platelet aggregation, and pentoxifylline, a xanthine-derived rheologic agent that reduces blood viscosity and enhances erythrocyte deformability.
By improving microvascular perfusion and lower-extremity blood flow without causing systemic hypotension, these agents primarily serve to increase pain-free and maximal walking distance in patients with chronic lower-extremity arterial occlusive disease.
-
nih.gov
Intermittent claudication agents comprise a therapeutic class of vasoactive and hemorheologic medications used to manage ischemic muscle pain and functional walking impairment resulting from peripheral artery disease The class primarily includes medications such as cilostazol, a phosphodiesterase-3 inhibitor that induces vasodilation and inhibits platelet aggregation, and pentoxifylline, a xanthine-derived rheologic agent that reduces blood viscosity and enhances erythrocyte deformability
-
nih.gov
Intermittent claudication agents comprise a therapeutic class of vasoactive and hemorheologic medications used to manage ischemic muscle pain and functional walking impairment resulting from peripheral artery disease By improving microvascular perfusion and lower-extremity blood flow without causing systemic hypotension, these agents primarily serve to increase pain-free and maximal walking distance in patients with chronic lower-extremity arterial occlusive disease
-
nih.gov
The class primarily includes medications such as cilostazol, a phosphodiesterase-3 inhibitor that induces vasodilation and inhibits platelet aggregation, and pentoxifylline, a xanthine-derived rheologic agent that reduces blood viscosity and enhances erythrocyte deformability
-
aafp.org
The class primarily includes medications such as cilostazol, a phosphodiesterase-3 inhibitor that induces vasodilation and inhibits platelet aggregation, and pentoxifylline, a xanthine-derived rheologic agent that reduces blood viscosity and enhances erythrocyte deformability
-
nih.gov
By improving microvascular perfusion and lower-extremity blood flow without causing systemic hypotension, these agents primarily serve to increase pain-free and maximal walking distance in patients with chronic lower-extremity arterial occlusive disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.